Other Non-current Assets - Narrative (Details) $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2024 USD ($) payment	Sep. 30, 2023 USD ($)	Jun. 30, 2020 USD ($)	Sep. 30, 2024 USD ($) payment	Sep. 30, 2023 USD ($)	Dec. 31, 2023 payment
Acquired Finite-Lived Intangible Assets [Line Items]
Revenues	$ 13,542	$ 13,002		$ 45,694	$ 37,377
Number of guaranteed royalty payments | payment	8
License agreement with Sunovion Pharmaceuticals, Inc.
Acquired Finite-Lived Intangible Assets [Line Items]
Minimum annual royalty receivable	$ 1,000		$ 1,000	$ 1,000
Number of annual royalty payments receivable | payment	4			4		5
Mitsubishi Tanabe Pharma America, Inc And Haisco For Exarvan
Acquired Finite-Lived Intangible Assets [Line Items]
Sales commissions and fees				$ 191
Royalty
Acquired Finite-Lived Intangible Assets [Line Items]
Revenues				$ (935)	$ (989)
Royalty | License agreement with Sunovion Pharmaceuticals, Inc.
Acquired Finite-Lived Intangible Assets [Line Items]
Revenues			$ 8,000